15 Jan 2020

Pharmac strikes provisional deal to fund breast cancer drug

From Summer Report, 7:50 am on 15 January 2020

Pharmac has struck a provisional deal to fund a breast cancer drug to extend women's lives.

Ibrance extends life expectancy for some breast cancer sufferers, by stopping or slowing down the progression of certain types. More than 50,000 people signed a petition last year urging drug be funded.

The Cancer Society's medical director Dr Chris Jackson spoke to Logan Church.